^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma

Published date:
04/11/2020
Excerpt:
We identified patients with unresectable HCC who were treated with sorafenib or lenvatinib...Responder rate was 40% (2/5) in patients with high baseline ANG2 and FGF19 levels who received sorafenib.
DOI:
10.1002/jgh3.12339